Mesalazine, tripterygium glycosides (DrugBank: Mesalazine, Tripterygium)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 96 | クローン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02044952 (ClinicalTrials.gov) | January 2014 | 19/1/2014 | Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission | Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission | Inflammatory Bowel Diseases;Crohn's Disease;Gastrointestinal Diseases;Digestive System Diseases;Intestinal Diseases | Drug: Mesalazine, Tripterygium glycosides | Zhu Weiming | NULL | Recruiting | 18 Years | 75 Years | Both | 40 | Phase 2;Phase 3 | China |